<ENAMEX TYPE="LOCATION">Britain</ENAMEX> s Monopolies and Mergers <ENAMEX TYPE="ORGANIZATION">Commission Wednesday</ENAMEX> cleared <ENAMEX TYPE="ORGANIZATION">Rhone Poulenc S A</ENAMEX> s purchase of a specialty bulk chemical unit from <ENAMEX TYPE="ORGANIZATION">Monsanto Co</ENAMEX> saying the purchase was unlikely to have any lasting impact on <ENAMEX TYPE="ORGANIZATION">U K</ENAMEX> industrial consumers The commission which was asked to study the deal by the <ENAMEX TYPE="ORGANIZATION">Department</ENAMEX> of <ENAMEX TYPE="ORGANIZATION">Trade</ENAMEX> and <ENAMEX TYPE="ORGANIZATION">Industry</ENAMEX> after its announcement in February said the diversity of global supply of chemicals used in making analgesic drugs was great enough to offset the dominant <ENAMEX TYPE="ORGANIZATION">U K</ENAMEX> market share <ENAMEX TYPE="ORGANIZATION">Rhone Poulenc</ENAMEX> would gain through the acquisition The French chemical giant would hold an 80 share of the <ENAMEX TYPE="ORGANIZATION">U K</ENAMEX> market for salicylic acid methyl salicylate and bulk aspirin The commission found that if the British government attempted to block the merger <ENAMEX TYPE="ORGANIZATION">Rhone Poulenc</ENAMEX> would likely respond by closing the salicylates plant <ENAMEX TYPE="ORGANIZATION">Monsanto</ENAMEX> operates in <ENAMEX TYPE="LOCATION">Wales</ENAMEX> removing the matter from <ENAMEX TYPE="ORGANIZATION">U K</ENAMEX> jurisdiction